Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0799 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0799 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0493 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0799 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0799 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0799 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0799 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0403 | 0.0151 | 0.0151 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0799 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0799 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0799 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0799 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0799 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0708 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0799 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0799 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0397 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0493 | 0.2407 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0708 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0799 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0799 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0799 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0799 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0799 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0799 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0799 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0799 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0397 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0799 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Active dose range (functional) | 0 mg kg-1 | Active dose range of the compound for antileukemic activity against L1210 mouse leukemia cells was reported ; ND means no data | ChEMBL. | 3656353 |
ED50 (functional) | = 0.3 ug ml-1 | In vitro cytotoxic activity against KB cell culture. | ChEMBL. | 3656353 |
No. of cures (functional) | In vivo antileukemic activity against L-1210 mouse leukemia cells given as number of animals cured out of 6 ; ND means no data | ChEMBL. | 3656353 | |
No. of cures (functional) | 0 | In vivo antileukemic activity against L-1210 mouse leukemia cells given as number of animals cured out of 6 ; ND means no data | ChEMBL. | 3656353 |
T/C (functional) | % | In vivo antileukemic activity against L-1210 mouse leukemia cells expressed as KE (log10 of initial tumor cell population minus log10 of tumor cell population at end of treatment); ND means no data | ChEMBL. | 3656353 |
T/C (functional) | % | In vivo antileukemic activity against L-1210 mouse leukemia cells expressed as % T/C (median survival time of treated/control animals) x 100; IA meansinactive | ChEMBL. | 3656353 |
T/C (functional) | 0 % | In vivo antileukemic activity against L-1210 mouse leukemia cells expressed as % T/C (median survival time of treated/control animals) x 100; IA meansinactive | ChEMBL. | 3656353 |
T/C (functional) | 0 % | In vivo antileukemic activity against L-1210 mouse leukemia cells expressed as KE (log10 of initial tumor cell population minus log10 of tumor cell population at end of treatment); ND means no data | ChEMBL. | 3656353 |
Toxic dose (ADMET) | 0 mg kg-1 | Toxic dose of the compound against L1210 mouse leukemia cells was determined; ND means no data | ChEMBL. | 3656353 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.